Accelr8 and Denver Health Notified by Department of Defense for Rapid Diagnostics Award
15 Mai 2012 - 12:00PM
Business Wire
Accelr8 Technology Corporation (NYSE MKT: AXK) and Denver
Health received notice that the Defense Medical Research and
Development Program (DMRDP) recommended $2 million funding of a
proposed 35-month project submitted jointly by Denver Health and
Accelr8. The DMRDP solicited proposals to “advance state-of-the-art
solutions for world-class medical care.”
The joint proposal became the sole recipient under the Military
Infectious Diseases Applied Research Award (MID-ARA) program for
rapid detection of serious antibiotic-resistant infections.
The project will apply Accelr8’s BACcel™ same-shift rapid
diagnostic system to wound infections and other serious infections
secondary to trauma. The intended scope encompasses the full range
from battlefield injuries at Level III field hospitals through
post-rehabilitation care, and medical care for veterans and their
dependents. The MID-ARA program’s purpose is “… to accelerate the
transition of medical technologies into deployed products; and to
accelerate the translation of advances in knowledge into new
standards of care in multiple military-relevant areas.”
Co-Principal Investigators are Ivor S. Douglas, M.D., and Connie
S. Price, M.D., from Denver Health. They are, respectively, the
Chief of the Division of Pulmonary and Critical Care Medicine, and
the Chief of the Division of Infectious Diseases Medicine. David
Howson, Accelr8’s president, is the co-investigator who will lead
the company’s development team. Collaborators include the
Department of Veterans Affairs Eastern Colorado Healthcare System
(Denver), the Washington Hospital Center (DC), and Creighton
University School of Medicine (Omaha, NE).
“Denver Health is delighted to secure this important grant with
our partner Accelr8 to advance the science of clinical microbiology
and therapeutics for critically ill and injured military personnel
and, by extension, civilians suffering from life-threatening
infections,” said Dr. Ivor Douglas.
David Howson, Accelr8’s president, said “we are honored to see
our unique diagnostic capability recognized through extensive peer
review for its potential value in serving the courageous men and
women of the military. Throughout history, infection has served as
a ‘third army’ causing severe casualties. Modern field medicine now
prevails over microbial contamination, but infections acquired
later during the course of care continue to cause grievous damage.
We are excited to have leadership by Denver Health and
collaboration with a growing network of premier research
institutions to make the case for our innovative technology in this
most deserving patient community.”
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer
of innovative materials and instrumentation for advanced
applications in medical instrumentation, basic research, drug
discovery, and bio-detection. Accelr8 is developing a rapid
analytical platform for infectious pathogens, the BACcel™ system,
based on its innovative assay processing and detection
technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Accelr8 (AMEX:AXK)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024